Edition:
United Kingdom

People: Aurinia Pharmaceuticals Inc (AUP.TO)

AUP.TO on Toronto Stock Exchange

8.72CAD
8:59pm BST
Change (% chg)

$0.06 (+0.69%)
Prev Close
$8.66
Open
$8.65
Day's High
$8.75
Day's Low
$8.59
Volume
25,373
Avg. Vol
67,818
52-wk High
$10.47
52-wk Low
$6.61

Martin, Michael 

Mr. Michael R. Martin is Chief Operating Officer of Aurinia Pharmaceuticals Inc. He was formerly CEO, director and co-founder of the privately held Aurinia Pharma Corp. which was acquired in 2013 by the Company. In his current role with Aurinia, Mr. Martin is responsible for managing company functions such as corporate and business development, alliance management, investor relations, intellectual property and pre-commercial market planning. Mr. Martin is a biotech/pharmaceutical executive with over 19 years industry experience. Mr. Martin joined Aurinia from Vifor Pharma where he held the position of Director, Global Business Development & Licensing. Prior to Vifor, Mr. Martin was a key member of the business development team that saw Aspreva sold to Galenica for $915M. Upon joining Aspreva in 2004, Mr. Martin initiated the strategic launch planning process for CellCept® in “less-common” autoimmune diseases. These included such indications as pemphigus vulgaris, myasthenia gravis, and lupus nephritis. Prior thereto, Mr. Martin held a variety of progressively senior commercial positions at Schering-Plough. Mr. Martin spent time in Europe where he was responsible for the rheumatology business unit for Remicade® in France. In addition while at Schering-Plough, Mr. Martin was the brand manager responsible for the Canadian launch of Remicade (infliximab).

Basic Compensation

Total Annual Compensation, CAD 404,793
Restricted Stock Award, CAD --
Long-Term Incentive Plans, CAD --
All Other, CAD --
Fiscal Year Total, CAD 404,793

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --